

ORAMED PHARMACEUTICALS INC.

Form 8-K

August 12, 2015

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): August 11, 2015

**Oramed Pharmaceuticals Inc.**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**

Edgar Filing: ORAMED PHARMACEUTICALS INC. - Form 8-K

(State or Other Jurisdiction of Incorporation)

**001-35813**

**98-0376008**

(Commission File Number) (IRS Employer Identification No.)

**Hi-Tech Park 2/4 Givat Ram, PO Box 39098,  
Jerusalem, Israel**

**91390**

(Address of Principal Executive Offices) (Zip Code)

**+972-2-566-0001**

(Registrant's Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

The Company held its annual meeting of stockholders on August 11, 2015. The final voting results are set forth below.

Stockholders voted on the following proposals:

**Proposal No. 1 — Re-election of Directors.**

The stockholders re-elected the following directors of the Company to hold office until the next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal. The votes were as follows:

| <b>Director Name</b> | <b>For</b> | <b>Against</b> | <b>Abstain</b> | <b>Broker<br/>Non-Votes</b> |
|----------------------|------------|----------------|----------------|-----------------------------|
| Nadav Kidron         | 3,469,253  | 101,687        | 14,717         | 3,322,933                   |
| Miriam Kidron        | 3,466,710  | 102,596        | 16,351         | 3,322,933                   |
| Leonard Sank         | 3,492,857  | 51,665         | 41,135         | 3,322,933                   |
| Harold Jacob         | 3,504,880  | 39,942         | 40,835         | 3,322,933                   |
| Michael Berelowitz   | 3,467,144  | 100,805        | 17,708         | 3,322,933                   |
| Gerald Ostrov        | 3,505,725  | 39,497         | 40,435         | 3,322,933                   |

**Proposal No. 2 — Ratification of Auditors.**

The stockholders ratified the appointment of Kesselman & Kesselman, certified public accountants in Israel, a member of PricewaterhouseCoopers International Limited, as the independent registered public accounting firm of the Company for the fiscal year ending August 31, 2015. The votes were as follows:

| <b>For</b> | <b>Against</b> | <b>Abstain</b> | <b>Broker<br/>Non-Votes</b> |
|------------|----------------|----------------|-----------------------------|
| 6,699,311  | 59,389         | 149,890        | N/A                         |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Oramed  
Pharmaceuticals Inc.**

Date: August 12, 2015 By: /s/ Nadav Kidron  
Name: Nadav Kidron  
Title: President and CEO